1. Li, PK, Szeto, CC, Piraino, B, et al. ISPD Peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36(5): 481–508.
Google Scholar | SAGE Journals2. Szeto, CC, Li, PKT. Peritoneal dialysis-associated peritonitis. Clin J Am Soc Nephrol 2019; 14(7): 1100–1105.
Google Scholar | Crossref | Medline3. Mancini, A, Piraino, B. Review of antibiotic dosing with peritonitis in APD. Perit Dial Int 2019; 39(4): 299–305.
Google Scholar | SAGE Journals4. Ling, CW, Sud, K, Van, C, et al. Pharmacokinetics of culture-directed antibiotics for the treatment of peritonitis in automated peritoneal dialysis: a systematic narrative review. Perit Dial Int 2021; 41(3): 261–272.
Google Scholar | SAGE Journals5. Htay, H, Cho, Y, Pascoe, EM, et al. Center effects and peritoneal dialysis peritonitis outcomes: analysis of a national registry. Am J Kidney Dis 2018; 71(6): 814–821.
Google Scholar | Crossref | Medline6. Al Sahlawi, M, Zhao, J, McCullough, K, et al. Variation in peritoneal dialysis–related peritonitis outcomes in the peritoneal dialysis outcomes and practice patterns study (PDOPPS). Am J Kidney Dis 2021; 79(1): S0272–S6386.
Google Scholar | Medline7. Perl, J, Davies, SJ, Lambie, M, et al. The peritoneal dialysis outcomes and practice patterns study (PDOPPS): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis. Perit Dial Int 2016; 36(3): 297–307.
Google Scholar | SAGE Journals8. Robinson, BM, Bieber, B, Pisoni, RL, et al. Dialysis outcomes and practice patterns study (DOPPS): its strengths, limitations, and role in informing practices and policies. Clin J Am Soc Nephrol 2012; 7(11): 1897–1905.
Google Scholar | Crossref | Medline9. De Vecchi, AF, Scalamogna, A, Finazzi, S, et al. Preliminary evaluation of incremental peritoneal dialysis in 25 patients. Perit Dial Int 2000; 20(4): 412–417.
Google Scholar | SAGE Journals10. Rüger, W, van Ittersum, FJ, Comazzetto, LF, et al. Similar peritonitis outcome in CAPD and APD patients with dialysis modality continuation during peritonitis. Perit Dial Int 2011; 31(1): 39–47.
Google Scholar | SAGE Journals11. Al Sahlawi, M, Bargman, JM, Perl, J. Peritoneal dialysis–associated peritonitis: suggestions for management and mistakes to avoid. Kidney Med 2020; 2(4): 467–775.
Google Scholar | Crossref | Medline12. Gilmore, JF, Kim, M, LaSalvia, MT, et al. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. Perit Dial Int 2013; 33(4): 353–357.
Google Scholar | SAGE Journals13. Huen, SC, Hall, I, Topal, J, et al. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am J Kidney Dis 2009; 54(3): 538–541.
Google Scholar | Crossref | Medline14. de Moraes, TP, Olandoski, M, Caramori, JCT, et al. Novel predictors of peritonitis-related outcomes in the BRAZPD cohort. Perit Dial Int 2014; 34(2): 179–187.
Google Scholar | Crossref | Medline15. Manley, HJ, Bailie, GR. Automated peritoneal dialysis symposium: treatment of peritonitis in APD: pharmacokinetic principles. Semin Dial 2002; 15(6): 418–421.
Google Scholar | Crossref | Medline16. Manley, HJ, Bailie, GR, Asher, RD, et al. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19(1): 65–70.
Google Scholar | SAGE Journals17. Manley, HJ, Bridwell, DL, Elwell, RJ, et al. Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin. Perit Dial Int 2003; 23(5): 469–474.
Google Scholar | SAGE Journals18. Stevenson, S, Tang, W, Cho, Y, et al. The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis. Perit Dial Int 2015; 35(2): 222–228.
Google Scholar | SAGE Journals19. Tang, W, Cho, Y, Hawley, CM, et al. The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis. Perit Dial Int 2014; 34(2): 219–226.
Google Scholar | SAGE Journals